Generic Medicine Info
May be taken with or without food.
Hypersensitivity. Chronic or active liver disease. Lactation.
Special Precautions
Patients with autoimmune disease (e.g. lupus erythematosus, psoriasis), immunodeficiency. Renal impairment. Children. Pregnancy. Monitoring Parameters Perform LFT before treatment and periodically (after 4-6 weeks of treatment). Monitor CBC for therapy >6 weeks in immunosuppressed patients.
Adverse Reactions
Significant: Depression, taste or smell disturbance, severe neutropenia, agranulocytosis, pancytopenia, thrombocytopenia, precipitation and exacerbation of cutaneous and systemic lupus erythematosus, exacerbation of psoriasis. Eye disorders: Changes in ocular lens and retina. Gastrointestinal disorders: Flatulence, dyspepsia, nausea, abdominal pain, diarrhoea. General disorders and administration site conditions: Fever; application site pain or irritation (topical). Metabolism and nutrition disorders: Decreased appetite. Musculoskeletal and connective tissue disorders: Arthralgia, myalgia. Nervous system disorders: Headache. Skin and subcutaneous tissue disorders: Pruritus, rash, urticaria.
Potentially Fatal: Hepatic failure, serious skin reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis, bullous dermatitis, drug rash with eosinophilia and systemic symptoms), thrombotic microangiopathy (e.g. thrombotic thrombocytopenic purpura, haemolytic uraemic syndrome).
Drug Interactions
Increased effect or plasma concentration with CYP2C9 and CYP3A4 inhibitors (e.g. cimetidine, fluconazole, amiodarone). Decreased effect or plasma concentration with rifampicin. Terbinafine increases the effect of TCAs (e.g. desipramine), beta-blockers (e.g. atenolol), SSRIs (e.g. escitalopram), MAOIs (e.g. rasagiline) by inhibiting CYP2D6 enzyme. Decreases the clearance of caffeine. Increases the clearance of ciclosporin.
CIMS Class
Antifungals / Topical Antifungals & Antiparasites
ATC Classification
D01BA02 - terbinafine ; Belongs to the class of antifungals for systemic use.
D01AE15 - terbinafine ; Belongs to the class of other antifungals for topical use.
Disclaimer: This information is independently developed by CIMS based on terbinafine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in